Plasmacytoid dendritic cells count in antiretroviral-treated patients is predictive of HIV load control independent of CD4+ T-cell count

Current HIV Research

Volumn 6, Issue 1, 2008, Pages 19-27

  Lichtner, Miriam ^a   Rossi, Raffaella ^a   Rizza, Maria C ^a   Mengoni, Fabio ^a   Sauzullo, Ilaria ^a   Massetti, Anna P ^a   Luzi, Giuseppe ^a   Hosmalin, Anne ^b,c   Mastroianni, Claudio M ^a   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INSTITUT COCHIN   (France)

^c INSERM   (France)

Author keywords

Antiretroviral therapy; CD4; Dendritic cells; HIV; Innate immunity; pDC

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; BIOLOGICAL MARKER;

ADULT; AGED; BONE MARROW CELL; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PLASMA CELL; PREDICTION; REVIEW; T CELL DEPLETION; VIREMIA; VIRUS LOAD; ARTICLE; BLOOD; CASE CONTROL STUDY; CELL COUNT; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; VIROLOGY;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CELL COUNT; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; IMMUNITY, NATURAL; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; VIRAL LOAD;

EID: 40449124735     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783571937     Document Type: Review

References (42)

1. Lundgren JD, Mocroft A. The impact of antiretroviral therapy on AIDS and survival. J HIV Ther 2006; 11: 36-38.
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
3. Autran B. Effects of antiretroviral therapy on immune reconstitution. Antivir Ther 1999; 4 (Suppl 3): 3-6.
4. Mastroianni CM, Lichtner M, Mengoni F, et al. Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. AIDS 1999; 13: 883-890.
5. Lange CG, Lederman MM. Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J Antimicrob Chemother 2003; 51: 1-4.
6. Jansen CA, Piriou E, De Cuyper IM, et al. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity. Antivir Ther 2006; 11: 105-116.
7. Hulgan T, Raffami S, Kheshti A, et al. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts 1350 lymphocytes/mm3. J Infect Dis 2005; 192: 950-957.
8. Moore D, Hogg R, Yip B, Craib K, Wood E, Montaner J. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/muL. HIV Med 2006; 7: 383-388.
9. Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007; 195: 425-431.
10. D'AmiCo R, Yang Y, Mildvan D, et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol 2005; 25: 106-115.
11. Siddique MA, Hartman KE, Dragileva E, et al. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J Infect Dis 2006; 194: 661-665.
12. Hengel RL, Kovacs JA. Surrogate markers of immune function in human immunodeficiency virus-infeeted patients: what are they surrogates for? J Infect Dis 2003; 188: 1791-1793.
13. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. Infect Dis 2003; 187: 1534-1543.
14. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104: 942-947.
15. Servet C, Zitvogel L, Hosmalin A. Dendrific cells in innate immune responses against HIV. Curr Mol Med 2002; 2: 739-756.
16. Muller-Trutwin M, Hosmalin A. Role for plasmacytoid dendritic cells in anti-HIV innate immunity. Immunol Cell Biol 2005, 83: 578-583.
17. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2: 151-161.
18. MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schimitz J, Hart DJ. Characterization of human blood dendritic cells subsets. Blood 2002; 100: 4512-4520.
19. Pacanowski J, Kahi S, Baillet M, et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001; 98: 3016-3021.
20. Donaghy H, Pozniak A, Gazzard B, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98: 906-912.
21. Hosmalin A, Lebon P. Type I inteiferon production in HIV-infected patients. J Leukoc Biol 2006; 80: 984-993.
22. Soumelis V, Scott I, Gheyas F, et al. Depletion of circulating natural type 4 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98: 906-912.
23. Pacanowski J, Develioglu L, Kamga I, et al. Early plasmacytoid dendritic cell changes predict plasrha HIV load rebound during primary infection. J Infect Dis 2004; 190: 1889-1892.
24. Lichtner M, Rossi I, Mengoni F, et al. Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response. Clin Exp Immunol 2006; 143: 329-337.
25. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 2001; 22: 312-316.
26. Groot F, van Capel TMM, Kapsenberg ML, Berkhout B, de Jong EC. Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood 2006; 108: 1957-1964.
27. Zhang Z, Zhao QX, Fu JL, et al. Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy. Chin Med J 2006; 119: 1949-1957.
28. Chen X, Wang B, Chang LJ. Induction of primary anti-HIV CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentviral vectors. Cell Immunol 2006; 243: 10-18.
29. Vuckovic S, Gardiner D, Field K, Champan GV. Monitoring dendritic cells in clinical practice using a new whole blood single-platform Tru CountTM assay. J Immunol Methods 2004; 284: 73-87.
30. Sciarra A, Lichmer M, Autran Gomez AM, et al. Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DCIIC+ (myeloid) in prostate adenocarcinoma patients. Prostate 2007; 67: 1-7.
31. Azzoni L, Rutstein RM, Chehimi J, Farabaugh MA, Nowmos A, Montaner LJ. Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children. J Infect Dis 2005; 191: 1451-1459.
32. Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis 2003; 187: 26-37.
33. Finke JS, Shodell M, Shah K, Siegal FP, Steinman RM. Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol 2004; 24: 647-652.
34. Almeida M, Cordero M, Almeida J, Orfao A. Persistent abnormalities in peripheral blood dendritic cells and monocytes from HIV-1-positive patients after 1 year of antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 41: 405-415.
35. Zhang Z, Fu J, Zhao Q, et al. Differential restoration of myeloid and plasmacytoid dendritic cells in HIV-1-infected children after treatment with highly active antiretroviral therapy. J Immunol 2006; 176: 5644-5651.
36. Chehimi J, Campbell DE, Azzoni L, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002; 168: 4796-4801.
37. Killian MS, Fujimura SH, Hecht FM, Levy JA. Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS 2006; 20: 1247-1252.
38. Azzoni L, Chehimi J, Zhou L, et al. Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. AIDS 2007; 21: 293-305.
39. Schmidt B, Fujimura SH, Martin JN, Levy JA. Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J Clin Immunol 2006; 26: 55-64.
40. Goicoechea M, Smith DM, Liu L, et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006; 194: 29-37.
41. Kwan WH, Helt AM, Maranon C, et al. Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. J Virol 2005; 79: 7291-7299.
42. Thiebaut R, Pellegrin I, Chene G, et al. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 × 10(6)cells/1. AIDS 2005; 19: 53-61.